Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6340691B1 · kind B1 · utility
17Cited by
18References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2000 |
| Grant date | Jan 22, 2002 |
| Priority date | — |
| Expiry date | Jan 27, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.